Quince Therapeutics Releases Phase 2a Data for LAM-001 in PH-ILD Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: Newsfilter
- Clinical Trial Results: In the Phase 2a study for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), LAM-001 demonstrated a 67.4-meter improvement in six-minute walk distance (6MWD) and a 33.9% reduction in pulmonary vascular resistance (PVR), indicating its potential to enhance lung function and provide new treatment options for patients.
- Study Design and Implementation: The 24-week study involved 10 adult patients, primarily assessing changes in peak oxygen uptake (VO2 max) and safety, with results showing improvements in functional class for all evaluable patients, supporting LAM-001's efficacy as an add-on therapy to standard care.
- Future Development Plans: Quince Therapeutics plans to initiate a Phase 2b trial in mid-2026, with topline data expected in the first quarter of 2028, reflecting the company's confidence in the ongoing development and market potential of LAM-001.
- Market Demand and Outlook: Patients with PH-ILD continue to face significant functional limitations despite existing therapies, and the positive results from LAM-001 may represent a crucial therapeutic advancement in the field, addressing the urgent need for new treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNCX
Wall Street analysts forecast QNCX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.170
Low
5.00
Averages
7.00
High
10.00
Current: 1.170
Low
5.00
Averages
7.00
High
10.00
About QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quince Therapeutics Acquires Orphai Therapeutics to Expand Pipeline
- Acquisition Overview: Quince Therapeutics announced the acquisition of clinical-stage biotech company Orphai Therapeutics, integrating Orphai's lead program LAM-001 into Quince's pipeline to treat rare pulmonary diseases, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Financing Arrangement: The acquisition is accompanied by a private placement financing agreement expected to raise up to $187 million in gross proceeds, including $115 million in upfront proceeds for purchasing non-voting convertible preferred stock, indicating strong market confidence in the deal.
- Equity Exchange Structure: The acquisition is structured as a stock-for-stock merger, where all outstanding equity interests of Orphai will be exchanged for 3.25 million shares of common stock, 67.1 million shares of non-voting convertible preferred stock, and options for 26.33 million shares of common stock, reflecting Quince's recognition of Orphai's value.
- Future Outlook: The transaction is expected to close on May 21, 2026, with Quince's stock price dropping 3.48% to $1.11 following the announcement; despite short-term volatility, the acquisition is poised to expand Quince's therapeutic areas and increase market share in the long run.
See More
LAM-001 Shows Significant Efficacy in PH-ILD Patients
- Clinical Trial Results: In a 24-week Phase 2a study involving 10 PH-ILD patients, the use of LAM-001 resulted in a 67.4-meter improvement in six-minute walk distance (6MWD) and a 33.9% reduction in pulmonary vascular resistance (PVR), demonstrating significant lung function improvement and indicating its potential value in treating refractory pulmonary arterial hypertension patients.
- Functional Improvement: All evaluable patients transitioned from Functional Class III to II by Week 24, with two patients achieving Class I status at 16 and 52 weeks, highlighting LAM-001's significant impact on enhancing patients' daily functioning and quality of life.
- Safety Assessment: LAM-001 was well tolerated against a background of standard therapy, with 6 evaluable patients, 4 of whom were PH-ILD patients, maintaining stable doses of treprostinil throughout the study, indicating its safety as an adjunct therapy.
- Future Development Plans: Quince Therapeutics plans to initiate a Phase 2b trial in mid-2026, with topline data expected in the first quarter of 2028, further validating LAM-001's efficacy in PH-ILD, reflecting the company's ongoing commitment to this field.
See More
LAM-001 Shows Significant Efficacy in PH-ILD Patients
- Clinical Trial Results: In a 24-week Phase 2a study involving 10 patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), LAM-001 demonstrated a significant improvement in six-minute walk distance (6MWD) by 67.4 meters and a reduction in pulmonary vascular resistance (PVR) by 33.9%, indicating its potential as a new treatment option for patients.
- Functional Improvement: All evaluable patients transitioned from Functional Class III to Class II by Week 24, with some even achieving Class I status at 16 and 52 weeks, suggesting LAM-001's potential to enhance daily functioning and significantly improve patients' quality of life.
- Safety Assessment: LAM-001 was generally well tolerated among patients receiving standard care, with 4 out of 6 evaluable patients being PH-ILD cases, indicating its safe use alongside existing therapies and enhancing its appeal as a potential treatment option.
- Future Research Plans: The company plans to initiate a Phase 2b trial in mid-2026, with topline data expected in the first quarter of 2028, further validating LAM-001's efficacy and safety, demonstrating the company's strong commitment to its development.
See More
Quince Acquires Orphai to Advance LAM-001 Development
- Acquisition Overview: Quince Therapeutics has acquired Orphai Therapeutics in a stock-for-stock merger, which includes 3,258,517 shares of common stock and 67,101.235 shares of Series C non-voting convertible preferred stock, expected to enhance Quince's market position in rare pulmonary diseases.
- Financing Support: The acquisition is accompanied by a private placement financing expected to raise up to $187 million, including $115 million in upfront proceeds, which will support multiple clinical milestones for LAM-001 and ensure operational funding through the end of 2028.
- Clinical Trial Plans: The Phase 2 clinical trial for LAM-001 is planned to initiate in mid-2026 targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), with data anticipated in Q1 2028, showcasing the company's strategic potential in addressing significant unmet medical needs.
- Market Outlook Analysis: LAM-001 targets PH-ILD and bronchiolitis obliterans syndrome (BOS), affecting approximately 86,000 and 17,000 patients in the U.S. and Europe respectively, indicating its market opportunity as a potential disease-modifying therapy, further solidifying Quince's leadership in the industry.
See More
LAM-001 Shows Significant Efficacy in PH-ILD Patients
- Clinical Trial Results: In patients with PH-ILD, the 24-week trial of LAM-001 demonstrated a significant improvement in six-minute walk distance (6MWD) by 67.4 meters and a reduction in pulmonary vascular resistance (PVR) by 33.9%, indicating the drug's potential to provide new treatment options for patients.
- Patient Transition Outcomes: All evaluable patients transitioned from Functional Class III to Class II by Week 24, with two patients achieving Class I status at 16 and 52 weeks, highlighting LAM-001's potential to enhance daily functioning and improve quality of life for patients.
- Safety and Tolerability: LAM-001 showed good tolerability among patients receiving standard background therapy, with 6 evaluable patients, 4 of whom were PH-ILD patients, maintaining stable doses of treprostinil throughout the study, suggesting the drug's safety profile is noteworthy.
- Future Research Plans: The company plans to initiate a Phase 2b trial in PH-ILD in mid-2026, with topline data expected in the first quarter of 2028, further validating LAM-001's efficacy and demonstrating the company's ongoing commitment to rare pulmonary diseases.
See More
Quince Acquires Orphai to Advance Pulmonary Disease Treatments
- Acquisition Overview: Quince Therapeutics has acquired Orphai Therapeutics in a stock-for-stock merger, which includes 3,258,517 shares of common stock and 67,101.235 shares of Series C non-voting convertible preferred stock, expected to enhance Quince's competitiveness in the rare pulmonary disease sector.
- Financing Support: The acquisition is accompanied by a private placement financing expected to raise up to $187 million, including $115 million in upfront proceeds, which will support multiple clinical milestones for LAM-001 and ensure operational funding through the end of 2028.
- Clinical Trial Plans: Quince plans to initiate a Phase 2b trial of LAM-001 in PH-ILD in mid-2026, with data anticipated in Q1 2028, while also providing Phase 2 data for BOS in Q1 2027, demonstrating the company's proactive approach in pulmonary disease treatment.
- Market Potential: LAM-001 targets approximately 86,000 patients in the U.S. and 120,000 in Europe suffering from PH-ILD, and Quince's acquisition and subsequent R&D efforts will help address this significant unmet medical need, enhancing patient quality of life.
See More
Quince Therapeutics Acquires Orphai Therapeutics to Expand Pipeline
- Acquisition Overview: Quince Therapeutics announced the acquisition of clinical-stage biotech company Orphai Therapeutics, integrating Orphai's lead program LAM-001 into Quince's pipeline to treat rare pulmonary diseases, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Financing Arrangement: The acquisition is accompanied by a private placement financing agreement expected to raise up to $187 million in gross proceeds, including $115 million in upfront proceeds for purchasing non-voting convertible preferred stock, indicating strong market confidence in the deal.
- Equity Exchange Structure: The acquisition is structured as a stock-for-stock merger, where all outstanding equity interests of Orphai will be exchanged for 3.25 million shares of common stock, 67.1 million shares of non-voting convertible preferred stock, and options for 26.33 million shares of common stock, reflecting Quince's recognition of Orphai's value.
- Future Outlook: The transaction is expected to close on May 21, 2026, with Quince's stock price dropping 3.48% to $1.11 following the announcement; despite short-term volatility, the acquisition is poised to expand Quince's therapeutic areas and increase market share in the long run.
See More
LAM-001 Shows Significant Efficacy in PH-ILD Patients
- Clinical Trial Results: In a 24-week Phase 2a study involving 10 PH-ILD patients, the use of LAM-001 resulted in a 67.4-meter improvement in six-minute walk distance (6MWD) and a 33.9% reduction in pulmonary vascular resistance (PVR), demonstrating significant lung function improvement and indicating its potential value in treating refractory pulmonary arterial hypertension patients.
- Functional Improvement: All evaluable patients transitioned from Functional Class III to II by Week 24, with two patients achieving Class I status at 16 and 52 weeks, highlighting LAM-001's significant impact on enhancing patients' daily functioning and quality of life.
- Safety Assessment: LAM-001 was well tolerated against a background of standard therapy, with 6 evaluable patients, 4 of whom were PH-ILD patients, maintaining stable doses of treprostinil throughout the study, indicating its safety as an adjunct therapy.
- Future Development Plans: Quince Therapeutics plans to initiate a Phase 2b trial in mid-2026, with topline data expected in the first quarter of 2028, further validating LAM-001's efficacy in PH-ILD, reflecting the company's ongoing commitment to this field.
See More
LAM-001 Shows Significant Efficacy in PH-ILD Patients
- Clinical Trial Results: In a 24-week Phase 2a study involving 10 patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), LAM-001 demonstrated a significant improvement in six-minute walk distance (6MWD) by 67.4 meters and a reduction in pulmonary vascular resistance (PVR) by 33.9%, indicating its potential as a new treatment option for patients.
- Functional Improvement: All evaluable patients transitioned from Functional Class III to Class II by Week 24, with some even achieving Class I status at 16 and 52 weeks, suggesting LAM-001's potential to enhance daily functioning and significantly improve patients' quality of life.
- Safety Assessment: LAM-001 was generally well tolerated among patients receiving standard care, with 4 out of 6 evaluable patients being PH-ILD cases, indicating its safe use alongside existing therapies and enhancing its appeal as a potential treatment option.
- Future Research Plans: The company plans to initiate a Phase 2b trial in mid-2026, with topline data expected in the first quarter of 2028, further validating LAM-001's efficacy and safety, demonstrating the company's strong commitment to its development.
See More
Quince Acquires Orphai to Advance LAM-001 Development
- Acquisition Overview: Quince Therapeutics has acquired Orphai Therapeutics in a stock-for-stock merger, which includes 3,258,517 shares of common stock and 67,101.235 shares of Series C non-voting convertible preferred stock, expected to enhance Quince's market position in rare pulmonary diseases.
- Financing Support: The acquisition is accompanied by a private placement financing expected to raise up to $187 million, including $115 million in upfront proceeds, which will support multiple clinical milestones for LAM-001 and ensure operational funding through the end of 2028.
- Clinical Trial Plans: The Phase 2 clinical trial for LAM-001 is planned to initiate in mid-2026 targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), with data anticipated in Q1 2028, showcasing the company's strategic potential in addressing significant unmet medical needs.
- Market Outlook Analysis: LAM-001 targets PH-ILD and bronchiolitis obliterans syndrome (BOS), affecting approximately 86,000 and 17,000 patients in the U.S. and Europe respectively, indicating its market opportunity as a potential disease-modifying therapy, further solidifying Quince's leadership in the industry.
See More
LAM-001 Shows Significant Efficacy in PH-ILD Patients
- Clinical Trial Results: In patients with PH-ILD, the 24-week trial of LAM-001 demonstrated a significant improvement in six-minute walk distance (6MWD) by 67.4 meters and a reduction in pulmonary vascular resistance (PVR) by 33.9%, indicating the drug's potential to provide new treatment options for patients.
- Patient Transition Outcomes: All evaluable patients transitioned from Functional Class III to Class II by Week 24, with two patients achieving Class I status at 16 and 52 weeks, highlighting LAM-001's potential to enhance daily functioning and improve quality of life for patients.
- Safety and Tolerability: LAM-001 showed good tolerability among patients receiving standard background therapy, with 6 evaluable patients, 4 of whom were PH-ILD patients, maintaining stable doses of treprostinil throughout the study, suggesting the drug's safety profile is noteworthy.
- Future Research Plans: The company plans to initiate a Phase 2b trial in PH-ILD in mid-2026, with topline data expected in the first quarter of 2028, further validating LAM-001's efficacy and demonstrating the company's ongoing commitment to rare pulmonary diseases.
See More
Quince Acquires Orphai to Advance Pulmonary Disease Treatments
- Acquisition Overview: Quince Therapeutics has acquired Orphai Therapeutics in a stock-for-stock merger, which includes 3,258,517 shares of common stock and 67,101.235 shares of Series C non-voting convertible preferred stock, expected to enhance Quince's competitiveness in the rare pulmonary disease sector.
- Financing Support: The acquisition is accompanied by a private placement financing expected to raise up to $187 million, including $115 million in upfront proceeds, which will support multiple clinical milestones for LAM-001 and ensure operational funding through the end of 2028.
- Clinical Trial Plans: Quince plans to initiate a Phase 2b trial of LAM-001 in PH-ILD in mid-2026, with data anticipated in Q1 2028, while also providing Phase 2 data for BOS in Q1 2027, demonstrating the company's proactive approach in pulmonary disease treatment.
- Market Potential: LAM-001 targets approximately 86,000 patients in the U.S. and 120,000 in Europe suffering from PH-ILD, and Quince's acquisition and subsequent R&D efforts will help address this significant unmet medical need, enhancing patient quality of life.
See More
